PMCB (PharmaCyte Biotech) Scaled Net Operating Assets: 0.34 (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.73
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Scaled Net Operating Assets?

PharmaCyte Biotech PMCB -3.81% 32 Scaled Net Operating Assets is 0.34 as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PharmaCyte Biotech's operating assets for the quarter that ended in Jan. 2026 was $35.34 Mil. PharmaCyte Biotech's operating liabilities for the quarter that ended in Jan. 2026 was $16.47 Mil. PharmaCyte Biotech's Total Assets for the quarter that ended in Oct. 2025 was $55.98 Mil. Therefore, PharmaCyte Biotech's scaled net operating assets (SNOA) for the quarter that ended in Jan. 2026 was 0.34.

PharmaCyte Biotech Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Scaled Net Operating Assets Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.61 0.05 -0.15 0.61

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.83 0.55 0.46 0.34

PMCB vs IMNN, ACXP, ENVB: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Scaled Net Operating Assets falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PharmaCyte Biotech's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Apr. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Apr. 2025 )
=(Operating Assets (A: Apr. 2025 )-Operating Liabilities (A: Apr. 2025 ))/Total Assets (A: Apr. 2024 )
=(39.63-3.277)/59.904
=0.61

where

Operating Assets(A: Apr. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=55.168 - 15.538
=39.63

Operating Liabilities(A: Apr. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.277 - 0 - 0
=3.277

PharmaCyte Biotech's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jan. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jan. 2026 )
=(Operating Assets (Q: Jan. 2026 )-Operating Liabilities (Q: Jan. 2026 ))/Total Assets (Q: Oct. 2025 )
=(35.336-16.471)/55.976
=0.34

where

Operating Assets(Q: Jan. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=55.874 - 20.538
=35.336

Operating Liabilities(Q: Jan. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16.471 - 0 - 0
=16.471

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.34 mean?
PharmaCyte Biotech (PMCB) has a Scaled Net Operating Assets of 0.34 as of Jan. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Scaled Net Operating Assets too high?
PharmaCyte Biotech's current Scaled Net Operating Assets is 0.34. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Scaled Net Operating Assets compare to IMNN and ACXP?
PharmaCyte Biotech's Scaled Net Operating Assets of 0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Scaled Net Operating Assets is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Scaled Net Operating Assets of 0.34. The current Scaled Net Operating Assets is 0.34. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Scaled Net Operating Assets is 0.34 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price